Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Japan, October 24, 2008 - Astellas Pharma Inc. (Astellas) announced today it has withdrawn a European marketing authorisation application (MAA) for telavancin, a bactericidal, once-daily...
Japan, October 6, 2008 - Astellas Pharma Inc. (headquarters: Tokyo, president and CEO: Masafumi Nogimori, “Astellas”) today announced that its serotonin 5-HT3 receptor antagonist Irribow®...
Read more about Astellas Launches Irribow® for the Treatment of Irritable Bowel Syndrome
Astellas Pharma Inc. (“Astellas”; President and CEO: Masafumi Nogimori) announced today that it has decided to dissolve its European subsidiary, Fujisawa Ireland Ltd. (headquarters: Kerry,...
Read more about Dissolution of the European Subsidiary Fujisawa Ireland Ltd.
Astellas Pharma Inc. (“Astellas”; Headquarters: Tokyo; President and CEO: Masafumi Nogimori) has completed the new buildings in its Tsukuba Research Center (Miyukigaoka) this September and...
Read more about Astellas Completes the New Buildings in its Tsukuba
Follow us
